Moleculin Biotech (MBRX) News Today $1.51 -0.03 (-1.95%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$1.52 +0.01 (+0.66%) As of 01/31/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Moleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.comFebruary 1 at 2:18 AM | americanbankingnews.comMBRX stock touches 52-week low at $1.46 amid sharp yearly declineJanuary 30 at 1:21 PM | msn.comMoleculin Biotech (NASDAQ:MBRX) CEO Participates in Virtual Investor Segment: 8-K Filing RevealsJanuary 29 at 3:15 AM | americanbankingnews.comMoleculin Biotech (NASDAQ:MBRX) CEO Participates in Virtual Investor "What this Means" segment - 8-K Filing NewsJanuary 28, 2025 | americanbankingnews.comContrasting Biora Therapeutics (NASDAQ:BIOR) and Moleculin Biotech (NASDAQ:MBRX)January 28, 2025 | americanbankingnews.comMoleculin Participates in Virtual Investor "What This Means" SegmentJanuary 27, 2025 | prnewswire.comStockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX)January 26, 2025 | americanbankingnews.comMoleculin Biotech (MBRX) Gets a Buy from Roth MKMJanuary 12, 2025 | markets.businessinsider.comMoleculin Biotech Shares Corporate Presentation UpdateJanuary 8, 2025 | tipranks.comMoleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 & 2026January 8, 2025 | prnewswire.comMoleculin Biotech Releases Corporate Presentation UpdateDecember 19, 2024 | markets.businessinsider.comMoleculin Biotech Inc MBRXDecember 11, 2024 | morningstar.comMoleculin Evaluates Prelim. Activity Of Annamycin In Acute Ara-C, VEN Resistant Myeloid LeukemiaDecember 11, 2024 | markets.businessinsider.comMoleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML ModelDecember 11, 2024 | prnewswire.comMoleculin Biotech Advances Annamycin for AML TreatmentNovember 18, 2024 | markets.businessinsider.comMoleculin Biotech announces new findings on AnnamycinNovember 18, 2024 | markets.businessinsider.comNew Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AMLNovember 18, 2024 | prnewswire.comMoleculin Biotech Unveils New Corporate PresentationNovember 14, 2024 | tipranks.comMoleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025November 14, 2024 | prnewswire.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | msn.comMoleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)November 12, 2024 | prnewswire.comMoleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | seekingalpha.comMoleculin Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 11, 2024 | prnewswire.comInsights Ahead: Moleculin Biotech's Quarterly EarningsNovember 7, 2024 | benzinga.comMoleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and WebcastNovember 5, 2024 | prnewswire.comMoleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of AnnamycinNovember 4, 2024 | prnewswire.comMoleculin Biotech’s Annual Meeting Decisions and ElectionsOctober 26, 2024 | markets.businessinsider.comMoleculin Biotech Highlights Annamycin’s AML Treatment PotentialOctober 18, 2024 | finance.yahoo.comTranscript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now AvailableOctober 17, 2024 | prnewswire.comMoleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ...October 11, 2024 | uk.finance.yahoo.comMoleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024October 7, 2024 | prnewswire.comMoleculin to Present at Two Upcoming Investor ConferencesOctober 4, 2024 | prnewswire.comMoleculin Biotech IncSeptember 25, 2024 | money.usnews.comMoleculin Biotech Sees Positive Data From Annamycin StudySeptember 24, 2024 | marketwatch.comMoleculin Biotech Shares Rise 12% After Positive Annamycin DataSeptember 24, 2024 | marketwatch.comMoleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of SarcomaSeptember 23, 2024 | prnewswire.comMoleculin Participates in Virtual Investor "What this Means" SegmentSeptember 16, 2024 | prnewswire.comMoleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of GlioblastomaSeptember 9, 2024 | prnewswire.comMoleculin to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | prnewswire.comMoleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment WebinarAugust 26, 2024 | prnewswire.comMoleculin Announces Closing of up to $16.5 Million Public OfferingAugust 19, 2024 | prnewswire.comMoleculin sets terms for $5.5 million public offeringAugust 18, 2024 | uk.investing.comMoleculin Biotech gets Buy rating from Roth with strong trial resultsAugust 16, 2024 | investing.comMoleculin Announces Pricing of up to $16.5 Million Public OfferingAugust 16, 2024 | finance.yahoo.comMoleculin Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 14, 2024 | prnewswire.comMoleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ETAugust 5, 2024 | prnewswire.comBuy Rating for Moleculin Biotech on Promising Annamycin Trials and Undervalued SharesAugust 2, 2024 | markets.businessinsider.comMoleculin Announces Plans for MIRACLE Phase 3 Pivotal TrialAugust 1, 2024 | prnewswire.comMoleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AMLJuly 10, 2024 | prnewswire.comMoleculin Announces Additional Positive Preliminary Interim Data from AML Clinical TrialJune 14, 2024 | prnewswire.com Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address MBRX Media Mentions By Week MBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MBRX News Sentiment▼0.040.69▲Average Medical News Sentiment MBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MBRX Articles This Week▼91▲MBRX Articles Average Week Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CARM News Today ATHE News Today ALLK News Today COCP News Today SNTI News Today MRKR News Today APRE News Today ATHA News Today LIAN News Today BFRG News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MBRX) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump loves DeepSeekPresident Trump could be ecstatic. And it's all thanks to DeepSeek. The secretive Chinese startup just r...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
